In our study (PPS population), the overall EGFR mutation frequency was 50.2%, similar to previous studies in East Asian patients [6,15], but much higher than in Caucasian lung adenocarcinoma patients [12,16]. Here, EGFR is linked to lung adenocarcinoma.